Recursion Pharmaceuticals (NASDAQ:RXRX) PT Lowered to $8.00

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price reduced by Leerink Partners from $9.00 to $8.00 in a report released on Tuesday morning, Benzinga reports. They currently have a market perform rating on the stock.

RXRX has been the subject of a number of other research reports. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a hold rating for the company in a report on Tuesday. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $17.00 to $16.00 and set a buy rating for the company in a report on Friday, August 9th. Finally, KeyCorp dropped their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an overweight rating for the company in a report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus target price of $9.40.

Recursion Pharmaceuticals Trading Down 4.1 %

Shares of RXRX opened at $5.92 on Tuesday. The stock has a fifty day moving average price of $7.33 and a two-hundred day moving average price of $8.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.07 and a current ratio of 6.07. Recursion Pharmaceuticals has a 52-week low of $4.97 and a 52-week high of $15.74. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -3.70 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) EPS. Analysts predict that Recursion Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $8.45, for a total value of $96,727.15. Following the completion of the sale, the director now directly owns 7,188,563 shares in the company, valued at $60,743,357.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total transaction of $374,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares of the company’s stock, valued at $5,675,360.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $8.45, for a total value of $96,727.15. Following the transaction, the director now directly owns 7,188,563 shares of the company’s stock, valued at $60,743,357.35. The disclosure for this sale can be found here. Insiders sold 243,129 shares of company stock worth $1,807,845 over the last ninety days. 15.75% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC boosted its position in shares of Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after buying an additional 3,555,357 shares during the period. Baillie Gifford & Co. boosted its position in shares of Recursion Pharmaceuticals by 10.5% during the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after buying an additional 2,522,132 shares during the period. Vanguard Group Inc. boosted its position in shares of Recursion Pharmaceuticals by 2.2% during the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company’s stock worth $159,667,000 after buying an additional 349,554 shares during the period. Mubadala Investment Co PJSC acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $128,041,000. Finally, Kinnevik AB publ boosted its position in shares of Recursion Pharmaceuticals by 14.4% during the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after buying an additional 1,500,000 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.